T1	PROC 47 149	Ensayo de fase II/III, multicéntrico, aleatorizado, con enmascaramiento doble y controlado con placebo
T2	PROC 155 207	evaluar la eficacia, la tolerabilidad y la seguridad
T3	Date 208 221	a largo plazo
T4	CHEM 225 238	sibeprenlimab
T5	PROC 239 270	administrado por vía subcutánea
T6	Route 256 270	vía subcutánea
T7	LIVB 273 282	pacientes
#1	AnnotatorNotes T7	C0030705; Patients; Patient or Disabled Group
T8	DISO 287 319	nefropatía por inmunoglobulina A
#2	AnnotatorNotes T8	C0017661; IGA Glomerulonephritis; Disease or Syndrome
T9	DISO 345 361	enfermedad renal
#3	AnnotatorNotes T9	C0022658; Kidney Diseases; Disease or Syndrome | C1542676; (Renal disease NOS) or (pyoureter); Disease or Syndrome
T10	DISO 402 416	de anticuerpos
T11	ANAT 424 431	riñones
#4	AnnotatorNotes T11	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T12	DISO 456 470	Nefropatía por
T13	CHEM 471 488	inmunoglobulina A
#5	AnnotatorNotes T13	C0020835; immunoglobulin A; Amino Acid, Peptide, or Protein · Immunologic Factor
T14	LIVB 517 524	Sujetos
#6	AnnotatorNotes T14	C0681850; Study Subject; Group
T15	PROC 599 605	visita
T16	PROC 683 689	visita
T17	Neg_cue 711 714	sin
T18	DISO 715 737	problemas de seguridad
T19	Negated 715 737	problemas de seguridad
T20	LIVB 760 772	investigador
#7	AnnotatorNotes T20	C0035173; Research Personnel; Professional or Occupational Group
T21	Spec_cue 774 781	podrían
T22	Speculated 782 794	beneficiarse
T23	Spec_cue 795 809	potencialmente
T24	PROC 814 825	tratamiento
#8	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	CHEM 830 843	sibeprenlimab
T26	DISO 852 856	NIgA
T27	LIVB 864 870	sujeto
#9	AnnotatorNotes T27	C0681850; Study Subject; Group
T28	PROC 881 884	FGe
T29	PROC 928 935	fórmula
T30	PROC 950 956	Kidney
T31	PROC 993 1000	CKD-EPI
T32	PROC 1034 1070	consentimiento informado por escrito
T33	PROC 1101 1114	procedimiento
T34	LIVB 1165 1187	investigador principal
#10	AnnotatorNotes T34	C1521895; Principal Investigator; Professional or Occupational Group
T35	LIVB 1267 1274	Sujetos
#11	AnnotatorNotes T35	C0681850; Study Subject; Group
T36	Neg_cue 1279 1281	no
T37	Negated 1288 1315	completado su participación
T38	LIVB 1362 1369	Sujetos
#12	AnnotatorNotes T38	C0681850; Study Subject; Group
T39	DISO 1374 1390	eventos adversos
#13	AnnotatorNotes T39	C0877248; Adverse event; Pathologic Function
T40	DISO 1392 1394	EA
#14	AnnotatorNotes T40	C0002395; Alzheimer's Disease; Disease or Syndrome | C0003507; Aortic Valve Stenosis; Disease or Syndrome | C0038013; Ankylosing spondylitis; Disease or Syndrome | C0947926; Alzheimer's disease (incl subtypes); Mental or Behavioral Dysfunction
T41	PROC 1413 1424	tratamiento
#15	AnnotatorNotes T41	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T42	LIVB 1517 1529	investigador
#16	AnnotatorNotes T42	C0035173; Research Personnel; Professional or Occupational Group
T43	Neg_cue 1534 1543	impediría
T44	Negated 1547 1574	transferencia a este ensayo
T45	LIVB 1611 1617	sujeto
#17	AnnotatorNotes T45	C0681850; Study Subject; Group
T46	Neg_cue 1618 1620	no
T47	Negated 1621 1676	cumplió repetidamente con los procedimientos del ensayo
T48	PROC 1651 1665	procedimientos
T49	LIVB 1765 1772	sujetos
#18	AnnotatorNotes T49	C0681850; Study Subject; Group
T50	Neg_cue 1794 1796	no
T51	Negated 1797 1814	cumplieron con el
T52	PROC 1827 1834	visitas
T53	PROC 1840 1852	evaluaciones
#19	AnnotatorNotes T53	C1261322; Evaluation procedure; Health Care Activity
T54	PROC 1869 1891	régimen de tratamiento
T55	LIVB 1915 1929	monitor médico
T56	LIVB 1936 1948	investigador
#20	AnnotatorNotes T56	C0035173; Research Personnel; Professional or Occupational Group
T57	Neg_cue 1949 1951	no
T58	Negated 1957 1963	seguro
T59	Speculated 1970 1982	elegibilidad
T60	LIVB 1989 1995	sujeto
#21	AnnotatorNotes T60	C0681850; Study Subject; Group
T61	LIVB 2000 2007	Sujetos
#22	AnnotatorNotes T61	C0681850; Study Subject; Group
T62	PROC 2047 2065	prueba de embarazo
#23	AnnotatorNotes T62	C0032976; Pregnancy Tests; Diagnostic Procedure
T63	LIVB 2091 2113	Varones heterosexuales
T64	LIVB 2139 2161	sujetos en edad fértil
T65	Age 2150 2161	edad fértil
T66	LIVB 2169 2176	parejas
#24	AnnotatorNotes T66	C0682323; Partner in relationship; Family Group
T67	Neg_cue 2182 2184	no
T68	Negated 2193 2235	cumplir con los requisitos anticonceptivos
T69	CHEM 2220 2235	anticonceptivos
#25	AnnotatorNotes T69	C0009871; Contraceptive Agents; Pharmacologic Substance
T70	PROC 2257 2271	consentimiento
T71	LIVB 2311 2317	sujeto
#26	AnnotatorNotes T71	C0681850; Study Subject; Group
T72	Duration 2333 2340	90 días
T73	LIVB 2354 2383	sujetos biológicos masculinos
T74	Duration 2387 2394	30 días
T75	LIVB 2396 2424	sujetos biológicos femeninos
